|
|
 |
|
Viewing report
|
|
|
|
Liver Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, Dec 2010, Pages: 49
Liver Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Liver Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global liver cancer market. The report identifies the key trends shaping and driving the global Liver cancer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Liver cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.
GlobalData valued the liver cancer market in 2009 at $382.2m, indicating a growth rate of 27.1% between 2001 and 2009. Until the market entry of Nexavar (sorafenib) in 2007, the liver cancer market was growing at a rate of only 9%. After the entry of Nexavar, the market registered a growth rate of 20% between 2007 and 2009. Until now, Nexavar has been the only approved drug for the treatment of liver cancer. Even though Nexavar extends overall survival by only three months, the drug is widely prescribed in the US and in some countries in Europe. The late-stage clinical development pipeline consists of many first-in-class and me-too drugs that are effective and safe for liver cancer patients. Once these drugs enter the market, the market will grow further at a significant rate. Therefore, GlobalData estimates that the liver cancer market in 2017 will be $1.2bn, indicating a compound annual growth rate (CAGR) of 15.5% between 2009 and 2017.
Scope
The report provides information on the key drivers and challenges of the Liver cancer market. Its scope includes:
- Annualized global Liver cancer market revenues data from 2001 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as mTOR inhibitors, Tyrosine kinase inhibitors, HDAC inhibitors, TNF-alpha inhibitors and Heparanase inhibitors.
- Analysis of the current and future competition in the global Liver cancer market. Key market players covered are AstraZeneca, Bayer, Celsion Corporation, Daichii Sankyo, Eli Lilly, and Otsuka Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Liver cancer therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Liver cancer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Liver cancer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Liver cancer market landscape? – Identify, understand and capitalize.
|
|
|
|
